| dc.contributor.author | Gill, DM | |
| dc.contributor.author | Iveson, M | |
| dc.contributor.author | Collins, I | |
| dc.contributor.author | Jones, AM | |
| dc.date.accessioned | 2018-01-24T12:49:58Z | |
| dc.date.issued | 2018-01-17 | |
| dc.identifier | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424308900010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
| dc.identifier.citation | TETRAHEDRON LETTERS, 2018, 59 (3), pp. 238 - 242 (5) | |
| dc.identifier.issn | 0040-4039 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1014 | |
| dc.identifier.doi | 10.1016/j.tetlet.2017.12.017 | |
| dc.description.abstract | The scope of an unexpected Mitsunobu cyclisation to prepare N-arylated Fsp3-enriched azacycles was investigated. In the current study, we have identified whether a pKa-dependent Mitsunobu cyclodehydration or a pKa-independent Mitsunobu intramolecular reaction was in operation. A Mitsunobu reaction, creating a leaving group, followed by intramolecular nucleophilic displacement was determined to be the dominant pathway. | |
| dc.format.extent | 238 - 242 (5) | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | |
| dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| dc.subject | Science & Technology | |
| dc.subject | Physical Sciences | |
| dc.subject | Chemistry, Organic | |
| dc.subject | Chemistry | |
| dc.subject | Mitsunobu | |
| dc.subject | Cyclodehydration | |
| dc.subject | Nucleophilic aromatic substitution | |
| dc.subject | Intramolecular | |
| dc.subject | Cyclisation | |
| dc.subject | INHIBITORS | |
| dc.subject | CYCLODEHYDRATION | |
| dc.subject | HSP70 | |
| dc.subject | PHASE | |
| dc.title | A Mitsunobu reaction to functionalized cyclic and bicyclic N-arylamines | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2017-12-04 | |
| rioxxterms.versionofrecord | 10.1016/j.tetlet.2017.12.017 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2018-01-17 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | TETRAHEDRON LETTERS | |
| pubs.issue | 3 | |
| pubs.notes | 24 months | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2 | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2 | |
| pubs.publication-status | Published | |
| pubs.volume | 59 | |
| pubs.embargo.terms | 24 months | |
| icr.researchteam | Medicinal Chemistry 2 | |
| dc.contributor.icrauthor | Collins, Ian | |
